Nexeon Medsystems (OTCMKTS:NXNN) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.


This table compares Nexeon Medsystems and electroCore’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nexeon Medsystems N/A N/A N/A
electroCore -4,450.22% -66.37% -60.41%

Analyst Ratings

This is a summary of current recommendations for Nexeon Medsystems and electroCore, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nexeon Medsystems 0 0 0 0 N/A
electroCore 0 2 1 0 2.33

electroCore has a consensus target price of $14.00, indicating a potential upside of 976.92%. Given electroCore’s higher possible upside, analysts plainly believe electroCore is more favorable than Nexeon Medsystems.

Institutional & Insider Ownership

15.2% of electroCore shares are owned by institutional investors. 61.2% of Nexeon Medsystems shares are owned by company insiders. Comparatively, 43.8% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Nexeon Medsystems and electroCore’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nexeon Medsystems $3.30 million 0.97 -$2.17 million N/A N/A
electroCore $990,000.00 38.91 -$55.82 million ($1.19) -1.09

Nexeon Medsystems has higher revenue and earnings than electroCore.


Nexeon Medsystems beats electroCore on 6 of the 10 factors compared between the two stocks.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

About electroCore

electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Nexeon Medsystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexeon Medsystems and related companies with's FREE daily email newsletter.